Executive Summary
In Q3 2025, Haemonetics Corporation reported a revenue of $348.5 million, marking a 4% increase year-over-year, albeit with flat organic growth. Notably, the adjusted earnings per share increased by 14% to $1.19, showcasing the company's ability to enhance profitability despite external challenges in the plasma collections market. The management acknowledged a strategic pivot following their divestiture of the whole blood business, allowing for better allocation of resources towards higher-margin segments. The continued momentum in both the Hospital and Interventional Technologies segments illustrates strong operational performance, which is expected to drive further growth in the upcoming fiscal years.
Key Performance Indicators
Key Insights
**Revenue Growth:** Q3 2025 revenue reached $348.5 million, up 4% YoY. Organic growth was flat, impacted by the planned CSL transition.
**Profit Margins:** Adjusted gross margin improved to 57.7%, up 240 basis points from the prior year, driven by better volume growth and product mix.
**Operating Income:** Adjusted operating income increased by 25.7% year-over-year, highlighting strong operational leverage.
**Net Income:** Q3 net income totaled $37.5 million, reflecting a 20.02% increase YoY,...
Financial Highlights
Revenue Growth: Q3 2025 revenue reached $348.5 million, up 4% YoY. Organic growth was flat, impacted by the planned CSL transition.
Profit Margins: Adjusted gross margin improved to 57.7%, up 240 basis points from the prior year, driven by better volume growth and product mix.
Operating Income: Adjusted operating income increased by 25.7% year-over-year, highlighting strong operational leverage.
Net Income: Q3 net income totaled $37.5 million, reflecting a 20.02% increase YoY, supported by improved operational efficiency.
Cash Flow: Year-to-date cash from operating activities was $65.2 million, down from $117.7 million last year, mainly due to increased working capital requirements.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
348.54M |
3.66% |
0.88% |
| Gross Profit |
193.55M |
8.82% |
3.26% |
| Operating Income |
59.03M |
28.39% |
14.18% |
| Net Income |
37.49M |
20.02% |
10.83% |
| EPS |
0.75 |
20.97% |
13.64% |
Key Financial Ratios
operatingProfitMargin
16.9%
operatingCashFlowPerShare
$0.87
freeCashFlowPerShare
$0.7
Management Commentary
Management Commentary Highlights:
1. Chris Simon remarked, "In plasma, we are gaining share, both in the U.S. and globally by providing customers with best-in-class solutions for safely lowering cost per liter."
2. Regarding future growth, Simon stated, "We are increasingly confident in the foundation we are building for outsized transformational growth with all parts of our company contributing to sustainable and profitable long-term success."
"We are achieving significant milestones in the evolution of our business, driving improved profitability and growth momentum as we navigate external market challenges..." - Chris Simon, CEO
â Chris Simon
"We remain confident in the long-term sustainable revenue and earnings growth contribution from our plasma business. End market demand for plasma-derived therapies is strong..." - Chris Simon, CEO
â Chris Simon
Forward Guidance
Management has adjusted its revenue guidance to anticipate a 3-5% growth on a reported basis for FY 2025, while maintaining organic growth projections flat to a decrease of 2-4%. The company continues to express confidence in the long-term performance of its hospital segment, with an updated expected growth rate of 24-26% on a reported basis. Furthermore, management maintains that improvements in plasma contributions will materialize as innovations are rolled out efficiently.